Definium Therapeutics (DFTX) Tax Provisions (2021 - 2022)
Definium Therapeutics' (DFTX) quarterly Tax Provisions came in at $224000.0 in Q4 2022, up 101.13% year-on-year from $111369.4 in Q4 2021, and up 101.13% on a QoQ basis from -$19.8 million in Q4 2021.
Definium Therapeutics (DFTX) Tax Provisions (2021 - 2022) Analysis & Trends
Definium Therapeutics (DFTX) has 2 years of Tax Provisions data on file, last reported at $224000.0 in Q4 2022.
- On a quarterly basis, Tax Provisions rose 101.13% year-over-year to $224000.0 in Q4 2022; TTM through Dec 2022 was -$19.6 million, a N/A change from a year earlier, with the FY2022 full-year figure at $224000.0, up 101.13% from the prior year.
- Tax Provisions for Q4 2022 stood at $224000.0, up from -$19.8 million in the prior quarter.
- Over the last five years, Tax Provisions for DFTX reached as high as $224000.0 in Q4 2022 and fell as low as -$19.8 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 125,146.46 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -859,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 31.86 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 221.50 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -60.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Definium Therapeutics | 4.71 Bn | 4.71 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 224,000.00 |
| Dec 31, 2021 | -19.78 Mn |